Plain-English translation of NCT06383559 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of three medications to treat advanced stomach cancer in patients whose tumors produce high levels of a protein called AFP. The combination includes standard chemotherapy (XELOX), an immunotherapy drug called Sintilimab that helps your immune system fight cancer, and a targeted therapy called Lenvatinib. An earlier study showed this combination was well-tolerated and promising, so researchers now want to confirm it works safely and effectively in a larger group of patients.
Most patients with advanced stomach cancer have limited treatment options. This medication combination was designed to attack cancer in multiple ways at once—killing cancer cells directly, boosting your immune system, and blocking tumor growth signals—which might work better than current standard treatments.
You will receive the three-drug combination every 3 weeks until your cancer stops responding, you experience severe side effects, or you and your doctor decide to stop treatment. The chemotherapy drugs are given intravenously (through an IV), while one medication is taken as a daily oral pill. You will have regular check-up visits, blood tests, and imaging scans every 6 weeks to monitor how well the treatment is working and check for side effects. The trial involves about 39 patients across multiple hospitals.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China